Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

547
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
547
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

490
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
490
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

542
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
542
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

525
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
525
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

691
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
691
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

208
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
208

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endocrine-related osteoporosis: the state of the art.

Frontiers in endocrinology·2026
Same author

Romosozumab super-responders in clinical practice: insights from a large Italian multicenter cohort of women with severe postmenopausal osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Management of patients with hypoparathyroidism: a Delphi consensus analysis.

Journal of endocrinological investigation·2026
Same author

Leptin/Adiponectin Ratio as a new multidimensional biomarker in obese patients with liver steatosis undergoing VLEKT: results from a pilot study.

Frontiers in nutrition·2026
Same author

Autotaxin and Lysophosphatidic Acid Circulating Levels Correlate with Body Mass Index in Obese Subjects with MASLD.

International journal of molecular sciences·2026
Same author

A Dose-Response Study on the Relationship Between Red Meat Intake and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Southern Italy: Results from the Nutrihep Study.

Nutrients·2026

Related Experiment Video

Updated: Jan 4, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.1K

Metformin: Up to Date.

Silvia Sciannimanico1, Franco Grimaldi1, Fabio Vescini1

  • 1Endocrinology and Metabolism Unit, University Hospital of Udine, Udine, Italy.

Endocrine, Metabolic & Immune Disorders Drug Targets
|November 1, 2019
PubMed
Summary

Metformin, a first-line type 2 diabetes medication, offers significant metabolic and non-metabolic benefits, including improved insulin sensitivity and anti-inflammatory effects. Its established efficacy and low cost ensure its continued importance in managing diabetes and related conditions.

Keywords:
Metforminheart failureinsulin resistancepolycystic ovary syndrometype 1 diabetestype 2 diabetes.

More Related Videos

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs
08:15

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Published on: August 15, 2025

954
Fixation and Operational Method for Abdominal Massage in T2DM Mice
05:57

Fixation and Operational Method for Abdominal Massage in T2DM Mice

Published on: March 7, 2025

664

Related Experiment Videos

Last Updated: Jan 4, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.1K
Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs
08:15

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Published on: August 15, 2025

954
Fixation and Operational Method for Abdominal Massage in T2DM Mice
05:57

Fixation and Operational Method for Abdominal Massage in T2DM Mice

Published on: March 7, 2025

664

Area of Science:

  • Pharmacology and Endocrinology
  • Metabolic Diseases
  • Immunology

Background:

  • Metformin is a widely prescribed oral hypoglycemic agent for type 2 diabetes.
  • It enhances insulin sensitivity, reduces hepatic glucose production, and increases muscle glucose uptake.
  • Beyond metabolic control, Metformin exhibits anti-inflammatory, immunomodulatory, and antineoplastic properties.

Purpose of the Study:

  • To provide a comprehensive review of the current literature on Metformin's metabolic and non-metabolic effects.
  • To summarize evidence regarding Metformin's diverse therapeutic applications.

Main Methods:

  • A narrative review of existing scientific literature.
  • Searches were conducted in PubMed using keywords and MeSH terms related to Metformin and various conditions (e.g., type 2 diabetes, PCOS).
  • Selection prioritized significant original articles and reviews published in English within the last five years.

Main Results:

  • Metformin demonstrates significant benefits in managing hyperglycemia and improving insulin sensitivity.
  • The drug also shows positive effects on weight management and possesses anti-inflammatory and immunomodulatory actions.
  • Evidence supports its role in conditions beyond type 2 diabetes, such as PCOS.

Conclusions:

  • Metformin remains a cornerstone therapy for type 2 diabetes due to its multifaceted benefits and cost-effectiveness.
  • Despite the availability of newer agents, Metformin's established efficacy and safety profile secure its place in clinical practice.
  • Its low cost and broad therapeutic actions make it invaluable for managing diabetes and its comorbidities.